|
Post by babaoriley on Mar 10, 2015 13:40:59 GMT -5
Okay, this is difficult for me, but...
This is my guess as to what is happening around these parts lately. For the short interests to come out with this slew of negative articles, downgrades, etc., lately, and actually highlighting the early Rx numbers (which I believe to be almost meaningless), makes me think that the shorties feel as if the Rx's are going to show marked improvement and a much better trend in the not too distant future, and that, therefore, they need to attack now on the Rx front, because soon that opportunity will be gone.
Now, of course, once the Rx numbers pick up for us, the shorts will attack on other fronts, they aren't going away anytime soon (sorry, Spiro), but, again, perhaps they feel it's their last chance to use Rx numbers to their advantage.
In connection with the above theory, I'm looking for a healthy increase in short interest on the next report date (Thursday, I believe, for end of Feb), which increase will reflect shorts preparing for the onslaught that began early the first week of March. I also am very much hoping to see a marked decrease for the period ending March 15, as some covered and took some decent profits, but of course, we won't get those numbers until the end of this month. Also, don't forget that shorts can do more than just short stock to profit from a declining share price, they may also have bought puts or sold uncovered calls.
Glad to see the upturn today - hopeful that we will sustain it through the close!
|
|
|
Post by otherottawaguy on Mar 10, 2015 13:57:56 GMT -5
Does anyone care to speculate where the next attack will be coming at?
ADCOM - Done FDA Approval - Done Partner - Done Launch Phase 1 - Done
Capacity Increase - how could this be spun negatively - too early ($$$) Capacity Increase - not enough (current vs lower project script , Capacity Increase - no demand (go read their play book for Launch P1) Q2/3/4 Calls - "where's the beef" ($$$ profit) Vocal Early Adopter Issue - one of those leading the charge has an issue they attempt to tie directly/indirectly to Afrezza Capacity Increase - Lines 4 through X have been order (see playbook for Cap Increases above Insider Sales - Dr Mann selling off any of his holdings (shares generated from warrants?) Sort Share Count - big decrease sparks a price jump Increasing PPS - short attack on PPS getting ahead of itself (wash, rinse, repeat) Launch Phase 2 - Tolero taking the lions share of Sale efforts. Sales at X month - Not reaching Sanofi goals, product line is going to be Exubera'd
Feel free to add more...I would be interested
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Mar 10, 2015 14:01:21 GMT -5
I mentioned this before, but the tact you will likely see is a bullish stance (but really bearish undercover) on scripts to share price. I predicted it before and it came to fruition with Psycho Analyst, but you'll start to see more of it. Things like "Lines 1 through 6 completely sold out are already built into the valuation". or "At a 5 P/E, this stock is adequately valued with 300,000 patients.
|
|
|
Post by joeypotsandpans on Mar 10, 2015 14:02:51 GMT -5
Does anyone care to speculate where the next attack will be coming at?
ADCOM - Done FDA Approval - Done Partner - Done Launch Phase 1 - Done
Capacity Increase - how could this be spun negatively - too early ($$$) Capacity Increase - not enough (current vs lower project script , Capacity Increase - no demand (go read their play book for Launch P1) Q2/3/4 Calls - "where's the beef" ($$$ profit) Vocal Early Adopter Issue - one of those leading the charge has an issue they attempt to tie directly/indirectly to Afrezza Capacity Increase - Lines 4 through X have been order (see playbook for Cap Increases above Insider Sales - Dr Mann selling off any of his holdings (shares generated from warrants?) Sort Share Count - big decrease sparks a price jump Increasing PPS - short attack on PPS getting ahead of itself (wash, rinse, repeat) Launch Phase 2 - Tolero taking the lions share of Sale efforts. Sales at X month - Not reaching Sanofi goals, product line is going to be Exubera'd
Feel free to add more...I would be interested
is that Canadian for Toujeo?
|
|
|
Post by babaoriley on Mar 10, 2015 14:03:45 GMT -5
Wow, nice rapid-fire list, OOG! For me, the most logical attack is always market cap, especially vs anticipated profits, which can be spun any which way. Here's one from left field: Does anyone think of Afrezzauser and/or Spiro as the Manchurian Candidate?
|
|
|
Post by otherottawaguy on Mar 10, 2015 14:19:40 GMT -5
I can't even spell Afrezza right, must be the cold weather up here in the Great White North.
Got to go now, wife is telling me to go take care of that polar bear that is circlin' the igloo.
OOG
|
|
|
Post by dreamboatcruise on Mar 10, 2015 14:43:38 GMT -5
Wow, nice rapid-fire list, OOG! For me, the most logical attack is always market cap, especially vs anticipated profits, which can be spun any which way. Here's one from left field: Does anyone think of Afrezzauser and/or Spiro as the Manchurian Candidate? You mean Angela Lansbury is really controlling Spiro's every move? That explains a lot.
|
|